Cargando…

Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer

OBJECTIVES: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Dong Woog, Kim, Chu Hyun, Hwang, Soohyun, Choi, Yoon-La, Cho, Jong Ho, Kim, Hong Kwan, Choi, Yong Soo, Kim, Jhingook, Shim, Young Mog, Shin, Sumin, Lee, Ho Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206049/
https://www.ncbi.nlm.nih.gov/pubmed/35715654
http://dx.doi.org/10.1186/s13244-022-01235-2
_version_ 1784729257929342976
author Yoon, Dong Woog
Kim, Chu Hyun
Hwang, Soohyun
Choi, Yoon-La
Cho, Jong Ho
Kim, Hong Kwan
Choi, Yong Soo
Kim, Jhingook
Shim, Young Mog
Shin, Sumin
Lee, Ho Yun
author_facet Yoon, Dong Woog
Kim, Chu Hyun
Hwang, Soohyun
Choi, Yoon-La
Cho, Jong Ho
Kim, Hong Kwan
Choi, Yong Soo
Kim, Jhingook
Shim, Young Mog
Shin, Sumin
Lee, Ho Yun
author_sort Yoon, Dong Woog
collection PubMed
description OBJECTIVES: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly. METHODS: We retrospectively investigated 944 patients with clinical stage IA NSCLC, who underwent curative-intent lung resection between August 2018 and January 2020. The CTR was measured and used to categorize patients into six groups (1, 0%; 2, 0–25%; 3, 25–50%; 4, 50–75%; 5, 75–100%; and 6, 100%). RESULTS: Pathologic nodal upstaging was found in 1.8% (group 4), 9.0% (group 5), and 17.4% (group 6), respectively. The proportion of patients with a high grade of tumor-infiltrating lymphocytes tended to decrease as the CTR increased. In a subtype analysis of patients with adenocarcinoma, all of the patients with predominant micro-papillary patterns were in the CTR > 50% groups, and most of the patients with predominant solid patterns were in group 6 (47/50, 94%). The multivariate analysis demonstrated that CTR 75–100% (hazard ratio [HR], 3.85; 95% confidence interval [CI], 1.58–9.36) and CTR 100% (HR, 5.58; 95% CI, 2.45–12.72) were independent prognostic factors for DFS, regardless of tumor size. CONCLUSION: We demonstrated that the CTR could provide various noninvasive clinicopathological information. A CTR of more than 75% is the factor associated with a poor prognosis and should be considered when making therapeutic plans for patients with early-stage NSCLC.
format Online
Article
Text
id pubmed-9206049
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-92060492022-06-19 Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer Yoon, Dong Woog Kim, Chu Hyun Hwang, Soohyun Choi, Yoon-La Cho, Jong Ho Kim, Hong Kwan Choi, Yong Soo Kim, Jhingook Shim, Young Mog Shin, Sumin Lee, Ho Yun Insights Imaging Original Article OBJECTIVES: Ground-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly. METHODS: We retrospectively investigated 944 patients with clinical stage IA NSCLC, who underwent curative-intent lung resection between August 2018 and January 2020. The CTR was measured and used to categorize patients into six groups (1, 0%; 2, 0–25%; 3, 25–50%; 4, 50–75%; 5, 75–100%; and 6, 100%). RESULTS: Pathologic nodal upstaging was found in 1.8% (group 4), 9.0% (group 5), and 17.4% (group 6), respectively. The proportion of patients with a high grade of tumor-infiltrating lymphocytes tended to decrease as the CTR increased. In a subtype analysis of patients with adenocarcinoma, all of the patients with predominant micro-papillary patterns were in the CTR > 50% groups, and most of the patients with predominant solid patterns were in group 6 (47/50, 94%). The multivariate analysis demonstrated that CTR 75–100% (hazard ratio [HR], 3.85; 95% confidence interval [CI], 1.58–9.36) and CTR 100% (HR, 5.58; 95% CI, 2.45–12.72) were independent prognostic factors for DFS, regardless of tumor size. CONCLUSION: We demonstrated that the CTR could provide various noninvasive clinicopathological information. A CTR of more than 75% is the factor associated with a poor prognosis and should be considered when making therapeutic plans for patients with early-stage NSCLC. Springer Vienna 2022-06-17 /pmc/articles/PMC9206049/ /pubmed/35715654 http://dx.doi.org/10.1186/s13244-022-01235-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Yoon, Dong Woog
Kim, Chu Hyun
Hwang, Soohyun
Choi, Yoon-La
Cho, Jong Ho
Kim, Hong Kwan
Choi, Yong Soo
Kim, Jhingook
Shim, Young Mog
Shin, Sumin
Lee, Ho Yun
Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer
title Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer
title_full Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer
title_fullStr Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer
title_full_unstemmed Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer
title_short Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer
title_sort reappraising the clinical usability of consolidation-to-tumor ratio on ct in clinical stage ia lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206049/
https://www.ncbi.nlm.nih.gov/pubmed/35715654
http://dx.doi.org/10.1186/s13244-022-01235-2
work_keys_str_mv AT yoondongwoog reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT kimchuhyun reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT hwangsoohyun reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT choiyoonla reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT chojongho reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT kimhongkwan reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT choiyongsoo reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT kimjhingook reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT shimyoungmog reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT shinsumin reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer
AT leehoyun reappraisingtheclinicalusabilityofconsolidationtotumorratioonctinclinicalstageialungcancer